Lilly Looks To Take POINT On Emerging Cancer Radiopharmaceutical Space

Lilly has agreed to pay $1.4bn to acquire Point even though the company’s two lead candidates are out-licensed to Lantheus. The deal looks like an early-stage play to build a strong position in an emerging field.